Does that mean HRT is safe now?

No — it means the broad warning language changed. Your personal risks still depend on your age, timing, route, dose, and health history, and a licensed clinician should review them with you.

What is the 10-year rule for HRT?

It's the idea that systemic HRT generally has a more favorable benefit-and-risk balance when started before age 60 or within 10 years of menopause. The 2026 labels point to this timing for women with moderate-to-severe hot flashes and night sweats.

Can I start HRT after age 60?

Possibly, but it usually needs a more careful, individual review. Age alone isn't the only factor.

Do I need progesterone with estrogen?

If you have a uterus and take systemic estrogen, clinicians typically add progesterone or a progestogen to protect the uterine lining.

Is vaginal estrogen safer than systemic HRT?

It's different. Low-dose vaginal estrogen is absorbed mostly where it's placed, with minimal spread through the body, and carries the clearest support of any estrogen therapy.

Is compounded "bioidentical" HRT FDA-approved?

No. Compounded hormones are not FDA-approved as finished products. ACOG and the National Academies recommend FDA-approved options first, with compounded therapy reserved for specific situations.

Does HRT prevent heart disease or dementia?

You shouldn't take it for those reasons. NICE specifically advises against using HRT to prevent heart disease or dementia.

What non-hormonal prescriptions are approved for hot flashes?

Two FDA-approved, hormone-free pills: Veozah (fezolinetant) and the newer Lynkuet (elinzanetant). Veozah carries a boxed warning for rare serious liver injury and needs liver blood-test monitoring.

Should I stop HRT because of my age?

Don't stop because of an article. If you and your clinician decide to stop, you can choose to taper gradually or stop at once — and your treatment should be reviewed regularly.

What should I do next?

Figure out your symptom and risk bucket, then talk to a licensed clinician about the right path — systemic HRT, vaginal estrogen, non-hormonal care, or specialist-first.

New HRT Guidelines 2026: What Actually Changed — and What Didn't

By The HRT Index Editorial Team · Last verified: June 5, 2026

Independent editorial research. Not reviewed by a clinician, and not a substitute for personal medical advice.

If you searched for the new HRT guidelines 2026, here's the short version. The biggest change is that the FDA approved new labels for a first group of six menopause hormone products in February 2026, removing the boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. A “boxed warning” is the FDA's strongest type of safety notice — a black box printed on the label. The change does notmean HRT is safe for everyone, and one boxed warning is staying. Here's exactly what changed, what didn't, and what it means for you.

What we checked:FDA and HHS announcements, the FDA's updated prescribing-information list, a JAMAcommentary by FDA leaders, statements from The Menopause Society, the 2026 International Menopause Society recommendations, NICE guideline NG23, ACOG's compounded-hormone consensus, and the National Academies' compounded-hormone report. Scope: Menopause and perimenopause hormone therapy for women. Does not cover gender-affirming HRT or testosterone replacement for men.

The 2026 HRT update in 30 seconds

Your question	The straight answer	What to do next
Did the FDA remove the HRT black box warning?	Yes — the risk statements for cardiovascular disease, breast cancer, and probable dementia, starting with six products in February 2026.	Check whether your exact product's label changed (we show you how below).
Does that mean HRT is safe for everyone?	No. The change updates the warning language; it does not erase your personal risks.	Review your own risk factors with a clinician.
Which products changed first?	Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring.	Check whether your product is on the FDA's updated-labels list.
Does age still matter?	Yes. The new labels point to systemic HRT for moderate-to-severe hot flashes and night sweats in women under 60 or within 10 years of menopause.	Know your age and years since your last period before your visit.
Is vaginal estrogen different?	Yes — it's low-dose, works mostly where you put it, and has the clearest support behind it.	Ask whether your symptoms are local (dryness, painful sex) or whole-body (hot flashes).
Did compounded “bioidentical” HRT become FDA-approved?	No. Compounded hormones are still not FDA-approved as finished products.	Ask whether an FDA-approved option fits you first.

👉 Not sure which row is you? Take our free 60-second HRT matching quiz — a few plain questions about your symptoms, age, and history, then a clear read on which conversation fits you.

What are the new HRT guidelines 2026?

The “new HRT guidelines 2026” aren't one document. They're a cluster of updates that landed close together: a major FDA change to drug warning labels, fresh international recommendations from the International Menopause Society, updates to the UK's NICE guideline, and supportive statements from U.S. menopause experts. The one concrete U.S. rule change is to FDA labeling — not a blanket statement that everyone should now take HRT.

When a friend says “the guidelines changed,” she might mean any of these — and they're not the same thing:

FDA drug labels — the official safety information on the medicine itself. This is what changed most visibly in the U.S.
Medical society position statements — guidance from expert groups like The Menopause Society (the leading U.S. nonprofit for menopause care). Its current position statement dates to 2022, and it publicly supported the FDA's move.
International clinical recommendations— like the International Menopause Society's detailed 2026 update (342 recommendations and 40 key messages).
UK guidance from NICE — the National Institute for Health and Care Excellence, which writes some of the most specific, widely cited menopause advice in the world.

They mostly agree on the big idea: for the right woman, started at the right time, modern hormone therapy is a reasonable choice. But they're different kinds of documents with different jobs.

A key definition that runs through everything: “Systemic” hormone therapy travels through your whole body — pills, patches, gels, sprays — and treats whole-body symptoms like hot flashes and night sweats. “Local” or “vaginal” estrogen is a low-dose product (cream, tablet, or ring) used right where the problem is, mostly for dryness and discomfort. Almost every important difference in the 2026 changes comes back to that split.

The 2026 HRT Guideline Change Tracker

Source	What changed in/around 2026	What did not change	Applies to	What it means for you
FDA (drug labels)	Approved changes to the first six products on Feb 12, 2026. Removed boxed-warning language on cardiovascular disease, breast cancer, and probable dementia.	The boxed warning for uterine cancer stays on estrogen-only systemic products. Other risks remain on the label.	Systemic + vaginal (FDA-approved)	The fear label changed. Your decision still depends on your individual history.
FDA (timing language)	New labels point to systemic HRT for moderate-to-severe hot flashes/night sweats in women under 60 or within 10 years of menopause.	Not a hard on/off switch at 60. Later starts can still be considered with careful review.	Systemic	“How do my age and timing change my decision?”
The Menopause Society	Current statement dates to 2022; backed the FDA move, especially for low-dose vaginal estrogen.	Did not say everyone should start HRT.	Systemic + vaginal	Clinical context — not proof the decision is automatic for you.
International Menopause Society	Published broad 2026 recommendations — 342 recommendations, 40 key messages.	Not a U.S. drug label or provider ranking.	All menopause care	Good for depth — but still has to become your next step.
NICE (UK)	NG23 carries detailed advice on route, early menopause, and a 2026 amendment on bleeding.	Still calls for individual benefit-and-risk discussion by type, route, dose, and history.	Systemic + vaginal	How to do HRT safely — read as principles, not U.S. law.
Compounded “bioidentical” hormones	No 2026 update made them FDA-approved.	ACOG and National Academies still say use FDA-approved options first.	Compounded	Don't confuse “compounded” with “FDA-approved.” More below.

What did the FDA actually change about the HRT warning?

On February 12, 2026, the FDA approved new labels for the first six menopause hormone products, removing the boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. The change followed a July 2025 expert panel, a November 2025 announcement, and a public comment period. It does not mean HRT carries no risk — and one boxed warning is staying.

What the FDA removed

Cardiovascular disease (heart disease)
Breast cancer
Probable dementia

The reasoning: those warnings grew out of the Women's Health Initiative study from 2002, and FDA leaders concluded the warnings no longer matched today's science or today's patients. In that study, the average woman was about 63 — more than a decade older than the typical age when women start HRT for symptoms.

What the FDA did not remove

The uterine (endometrial) cancer warning stays on systemic estrogen-only products. If you have a uterus and take estrogen alone, that warning exists for a real reason — which is why women with a uterus are usually given a progestogen alongside estrogen.
The other risks didn't vanish.They're still listed in the prescribing information. Removing a warning from the boxisn't the same as declaring the risk gone.
HRT is still prescription medicine. It still needs a clinician and individual screening.

The FDA also approved two other things in late 2025: the first generic version of Premarin (conjugated estrogens) in over 30 years, and a non-hormonal option for hot flashes (named below).

Worth knowing: Many doctors agreed enthusiastically with the change for vaginal estrogen but raised questions about how the systemic-HRT labels were changed, since pulling a boxed warning usually involves a longer, more public review. A resource you can trust tells you the messy parts too.

Which HRT products had the warning removed first?

The first six products to get the new label, in February 2026, were Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring. Because 29 manufacturers submitted proposed updates, more products are expected to be relabeled over time.

Bijuva — estrogen + progesterone combination
Divigel, Cenestin, Enjuvia — estrogen-only
Prometrium — progesterone, for women with a uterus who use systemic estrogen
Estring — vaginal estrogen

How to check whether your product actually changed (two minutes):

Find the exact product name on your box, pharmacy label, or patient portal.
Look it up on the FDA's Menopausal Hormone Therapies with Updated Prescribing Information page (the list grows as more products are relabeled).
Look for the words “boxed warning,” plus your dose, route, and indication.
Ask your clinician: “Has my specific product's label changed, or is this a class-wide news story?”

Is HRT safe now that the warning is gone?

Removing a warning label changes the messaging, not the medicine. The evidence is most reassuring for healthy women who start within about 10 years of menopause or before age 60, and the clearest agreement of all is behind low-dose vaginal estrogen. But systemic hormone therapy still carries real risks that depend on your age, timing, dose, and health history — so it remains a personal, clinician-guided decision.

The 2026 change is not a permission slip. It does not mean every woman should start HRT, and it does not mean you can skip a real medical check. If you have unexplained vaginal bleeding, a history of hormone-sensitive cancer, blood clots, stroke, heart disease, or liver disease, the right next step is a clinician — not a fast online order.

Dr. Stephanie Faubion of the Mayo Clinic, medical director for The Menopause Society, has said the boxed warning “acted as a deterrent to the use of all hormone therapy” — meaning it scared off women who could have benefited. But the link between hormone therapy and breast cancer is complex and depends heavily on the regimen, the patient, and the timing. Oncologist Dr. Tiffany Troso-Sandoval made the practical line clear: vaginal estrogen is broadly fine for most patients, but systemic estrogen “still requires a fairly nuanced expert discussion.”

👉 You don't have to figure out where you fit alone. Our free 60-second matching quiz asks about your symptoms, age, and history, then gives you a plain-English read on which conversation fits you. Take the free 60-second HRT path quiz →

Who is HRT most likely to fit under the 2026 guidance?

Hormone therapy is most clearly worth discussing if you have bothersome menopause symptoms — especially hot flashes or night sweats — and you're under 60 or within 10 years of menopause. It can also be relevant for early menopause, premature ovarian insufficiency, vaginal and urinary symptoms, or bone protection in selected cases.

If this is you	What the 2026 changes generally mean	What to discuss with a clinician
Under 60, within 10 years of menopause, healthy, with hot flashes or night sweats	This is the group the evidence supports most. Healthy women in this window usually see more benefit than risk.	The best route and dose for you
Over 60, or more than 10 years past menopause	The warning change doesn't make this automatic; the benefit-vs-risk balance needs a closer look.	Whether the benefits still outweigh the risks for you
Personal history of breast cancer	The label change does not clear systemic HRT for you. This stays individualized, often oncologist-led.	Non-hormonal options first; specialist input
Mainly vaginal dryness, painful sex, or urinary discomfort	This is where agreement is clearest. Low-dose vaginal estrogen is widely supported.	Whether local estrogen fits
You have a uterus	You'll typically need progesterone alongside systemic estrogen — that's what the retained uterine-cancer warning is about.	A combined regimen
Early menopause or premature ovarian insufficiency (POI)	Different rules apply. NICE generally recommends hormone treatment until at least the usual age of menopause.	An early-menopause plan, not a standard one
You declined HRT years ago because of the scary warning	The reason you were frightened off has been re-examined. Whether it's right for you now is a fresh conversation.	A clean-slate review
You're already on HRT	Nothing is recalled. The change reframes the safety message; it doesn't force you to act.	Whether your current regimen still fits

👉 Found yourself in more than one row? Most women do. Get my HRT path →

Who should be more cautious, or see a specialist first?

Some women should treat the 2026 update as a reason to talk to a clinician, not as a green light for fast online prescribing. A history of breast cancer, blood clots, stroke, heart disease, complex medical conditions, or any unexplained vaginal bleeding should trigger a more careful — sometimes specialist-led — conversation.

A personal history or high risk of breast cancer. NICE recommends offering these women full information on all options and a referral to a clinician with menopause expertise. Online subscription HRT is usually the wrong front door.
A history of blood clots (VTE) or high clot risk. The route of estrogen matters a lot here, and NICE suggests sending people at high clot risk to a blood specialist before starting HRT.
A history of heart disease or stroke. NICE says this should be discussed — and offered only if appropriate — by a clinician with menopause expertise.
Unexplained or unexpected vaginal bleeding. NICE's 2026 guidance says to seek medical help promptly for unscheduled bleeding continuing beyond 6 months of starting systemic HRT, or beyond 3 months after changingdose or preparation — and sooner if it's heavy or worrying.

Does the 10-year rule still matter?

Yes — but it's a decision framework, not a cliff. The 2026 FDA labels point to considering systemic hormone therapy for moderate-to-severe hot flashes and night sweats in women under 60 or within 10 years of menopause onset. Starting later isn't automatically off-limits, but it calls for a more careful, individual review.

What it means

Measured from menopause onset
Usually travels with the under-60 marker
Applies mainly to systemic HRT for symptoms

What it does not mean

Not every woman under 60 should take HRT
Not every woman over 60 is automatically locked out
It doesn't override your medical history

Is vaginal estrogen different from systemic HRT?

Yes, and it's one of the most important distinctions on this page. Vaginal estrogen is a low-dose product used for local symptoms like dryness, painful sex, and urinary discomfort — together called GSM (genitourinary syndrome of menopause). It's absorbed mostly where you place it, with minimal spread through the body, which is why it carries the clearest support and the lowest level of concern of any estrogen therapy.

Systemic HRT is for whole-body symptoms (hot flashes, night sweats); vaginal estrogen is for the specific tissues where the problem is.

Why the warning conversation is different:because so little reaches the rest of your body, the risk picture isn't the same as for pills or patches. NICE notes that vaginal estrogen is absorbed locally with minimal systemic absorption, and serious side effects are very rare. Both the FDA and The Menopause Society singled out low-dose vaginal estrogen for the clearest support.

If you've had breast cancer: NICE recommends trying non-hormonal moisturizers and lubricants first, with vaginal estrogen only if those don't help — and with specialist coordination for women on certain breast-cancer medicines. Don't start vaginal estrogen on your own in this situation.

👉 If your main problem is dryness, painful sex, or urinary discomfort — not hot flashes — you may be on a different path than you think. Check my symptom path →

Patches vs pills: does the new guidance favor one?

The 2026 updates don't make patches mandatory, but the route you take estrogen does change your risk in one clear way. For women at higher risk of blood clots, transdermal estrogen (patch, gel, or spray) is generally preferred over oral estrogen (pills), because pills raise clot risk in a way skin delivery does not.

Transdermaljust means “through the skin.” Oral estrogen passes through your liver first, which is part of why it raises clot risk more than the skin route. NICE recommends considering transdermal rather than oral HRT for women at increased clot risk, including a BMI over 30. NICE also notes that oral (but not transdermal) estrogen is linked to a small increase in stroke risk.

The single most useful question to ask:

“Given my age, weight, blood pressure, and any clot, stroke, or migraine history, would oral or transdermal estrogen make more sense for me?”

Are compounded “bioidentical” hormones part of the 2026 changes?

No. The FDA's 2026 label changes apply to FDA-approved products only. They did not make compounded hormones FDA-approved. ACOG says compounded “bioidentical” menopausal hormone therapy should not be routinely prescribed when an FDA-approved option exists, and the National Academies recommends limiting compounded hormones to people who genuinely can't use an approved product.

Term	What it means	FDA-approved?
FDA-approved	The finished product was tested and cleared by the FDA for quality, safety, and effectiveness.	Yes
Bioidentical	The hormone is chemically the same as what your body makes. Many FDA-approved products are already bioidentical — for example, FDA-approved estradiol and micronized progesterone.	Some are (the FDA-approved ones); some aren't (compounded ones)
Compounded	A pharmacy custom-mixes the product. Does not go through FDA testing for purity, dose consistency, or quality.	No

Questions to ask before choosing compounded HRT:

“Is there an FDA-approved version that fits me first?”
“Is this specific product FDA-approved? If not, what does that mean for me?”
“What pharmacy compounds it, and how is dose consistency handled?”
“What's the follow-up and dose-adjustment plan?”

If you're weighing FDA-approved versus compounded options across telehealth services, our independent comparison of HRT telehealth providers breaks down which ones lead with FDA-approved care, what they cost, and who each one is best for.

What about testosterone for menopause?

Testosterone is not a 2026 menopause shortcut for energy, weight loss, mood, or “anti-aging.” In menopause care, it belongs in a narrow, monitored discussion — most commonly for low sexual desire when standard hormone therapy hasn't helped. There is no FDA-approved testosterone product specifically for menopausal symptoms in women, so this use is off-label, prescription-only, and best done with a knowledgeable clinician.

Where testosterone may genuinely fit: low sexual desire associated with menopause, after other causes are considered, and when estrogen therapy alone hasn't done the job. NICE supports considering it for exactly that situation.

Where it should not be oversold: as a treatment for fatigue, weight, mood, memory, or longevity. ACOG specifically recommends against testosterone pellets— because of a lack of safety data and because a pellet can't be removed once placed.

For U.S. readers: testosterone is a federally Schedule III controlled substance — it always requires a proper prescription and clinical oversight. Be cautious with any service that makes getting it sound casual.

What non-hormonal options are there in 2026?

Non-hormonal options matter because not everyone can or wants to take hormones. Two FDA-approved, hormone-free prescription medicines now exist for hot flashes, plus a well-supported talk-therapy approach — so a “no” to HRT is not a dead end.

Option	What it is	Key 2026 facts to know
Veozah (fezolinetant)	FDA-approved, non-hormonal pill for moderate-to-severe hot flashes (approved 2023).	Carries an FDA boxed warning for rare but serious liver injury. Liver blood test required before starting, monthly for first 3 months, then at months 6 and 9.
Lynkuet (elinzanetant)	Newer FDA-approved, non-hormonal pill for moderate-to-severe hot flashes (approved October 2025).	Not a hormone. Liver blood work before starting. Not for severe liver or kidney problems, or pregnancy. No boxed warning.
Menopause-specific CBT	Cognitive behavioral therapy — a structured, practical form of talk therapy.	NICE recommends it for hot flashes, sleep problems, and low mood tied to menopause. No prescription needed.

What to be careful with:NICE is blunt that the safety and effectiveness of unregulated hormone preparations are simply unknown. “Natural” is a marketing word, not a safety rating.

For a fuller breakdown, see our non-hormonal HRT alternatives guide.

Do you need blood tests before starting HRT?

Usually not. If you're 45 or older with typical symptoms and changing or stopped periods, menopause is diagnosed from your symptoms — not from a hormone blood test. Tests like FSH are mainly useful for younger women or unclear cases.

When testing usually isn't needed

You're 45 or older with typical symptoms. Both NICE and MedlinePlus agree testing usually isn't necessary at this stage — hormone levels swing day to day and don't add much to a clinical diagnosis.

When testing may matter

You're under 40 with possible premature ovarian insufficiency; you're 40–45 with symptoms; your symptoms are confusing; or your history changes the safety screening.

What should you ask your clinician after the 2026 HRT updates?

The best next step isn't “ask for HRT.” It's “ask which HRT conversation applies to me.” Walk in with your symptoms, age, years since your last period, whether you have a uterus, your personal and family history, your current medicines, and your preference for FDA-approved versus compounded options.

“Am I a reasonable candidate for systemic HRT, vaginal estrogen, a non-hormonal option, or a specialist-first evaluation?”
“Am I under 60 or within 10 years of menopause — and how does that change my benefit-and-risk picture?”
“Do I have a uterus, and would I need progesterone with systemic estrogen?”
“Would oral or transdermal estrogen be safer for my risk profile?”
“Are my symptoms whole-body, local/vaginal, or both?”
“Does any part of my personal or family history change the decision?”
“Is the medicine you're suggesting FDA-approved or compounded?”
“What should I expect at my 3-month review?” (Guidelines suggest reviewing at about 3 months, then yearly.)
“What bleeding is normal, and when should I call you?”
“What are my non-hormonal options if HRT isn't right for me?”

👉 Want these turned into a personalized checklist? Take the 60-second quiz and we'll build a question list that matches your symptom pattern and risk bucket — so the appointment works for you.

How we verified this 2026 HRT guideline summary

We built this page from official and high-authority sources, then translated them into a patient-facing decision guide. We did not use Reddit, forums, or testimonials as medical evidence.

What we verified: which warnings were removed from the boxed warning, and which one stayed; which six products were relabeled first, and that more are expected; the timing language the FDA added (under 60 / within 10 years); why vaginal estrogen is treated differently from systemic HRT; that compounded hormones did not become FDA-approved; clinical points on route, early menopause, testosterone, non-hormonal medicines, and testing, from the FDA, NICE, ACOG, and U.S. sources.

What we can't verify for you — and no honest website can: your personal eligibility, your insurance coverage, your exact prescription, or your clinician's medical judgment. That's the line between useful information and actual medical care.

New HRT guidelines 2026: FAQ

Quick answers for the questions readers ask most. For anything involving your risk or eligibility, see the full sections above — and talk to a clinician.

Did the FDA remove the black box warning from HRT?: Yes. In February 2026, the FDA approved new labels for the first six menopause hormone products, removing boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. The uterine-cancer warning stays on estrogen-only systemic products.
Does that mean HRT is safe now?: No — it means the broad warning language changed. Your personal risks still depend on your age, timing, route, dose, and health history, and a licensed clinician should review them with you.
Which HRT products were updated first?: Bijuva, Divigel, Cenestin, Enjuvia, Prometrium, and Estring. Because 29 manufacturers submitted proposed changes, more products are expected to follow.
What is the 10-year rule for HRT?: It's the idea that systemic HRT generally has a more favorable benefit-and-risk balance when started before age 60 or within 10 years of menopause. The 2026 labels point to this timing for women with moderate-to-severe hot flashes and night sweats.
Can I start HRT after age 60?: Possibly, but it usually needs a more careful, individual review. Age alone isn't the only factor.
Do I need progesterone with estrogen?: If you have a uterus and take systemic estrogen, clinicians typically add progesterone or a progestogen to protect the uterine lining.
Is vaginal estrogen safer than systemic HRT?: It's different. Low-dose vaginal estrogen is absorbed mostly where it's placed, with minimal spread through the body, and carries the clearest support of any estrogen therapy.
Is compounded "bioidentical" HRT FDA-approved?: No. Compounded hormones are not FDA-approved as finished products. ACOG and the National Academies recommend FDA-approved options first, with compounded therapy reserved for specific situations.
Does HRT prevent heart disease or dementia?: You shouldn't take it for those reasons. NICE specifically advises against using HRT to prevent heart disease or dementia.
What non-hormonal prescriptions are approved for hot flashes?: Two FDA-approved, hormone-free pills: Veozah (fezolinetant) and the newer Lynkuet (elinzanetant). Veozah carries a boxed warning for rare serious liver injury and needs liver blood-test monitoring.
Should I stop HRT because of my age?: Don't stop because of an article. If you and your clinician decide to stop, you can choose to taper gradually or stop at once — and your treatment should be reviewed regularly.
What should I do next?: Figure out your symptom and risk bucket, then talk to a licensed clinician about the right path — systemic HRT, vaginal estrogen, non-hormonal care, or specialist-first.

Still not sure what the new HRT guidelines mean for you?

The 2026 updates can tell you what changed on the label. They can't tell you your personal next step — that depends on your symptoms, your age, your history, where you live, and whether you want FDA-approved or compounded care.

Not sure which HRT program is right for you?

Our free 60-second matching quiz asks about your symptoms, your state, your insurance, and the kind of care you want — then points you toward the path most likely to fit.

Take the free 60-second matching quiz →

When you're ready to compare your options, our independent comparison of HRT telehealth providers walks through who leads with FDA-approved care, what they cost, and who each one is best for. Some links there are affiliate links — see our disclosure — but they never change our editorial conclusions. This page carries no affiliate links.

About this page

Written by: The HRT Index Editorial Team — The HRT Index, an independent comparison resource for HRT telehealth providers.

Review status: Independent editorial research. Not reviewed by a clinician, and not a substitute for personal medical advice.

Last verified: June 5, 2026

How we make money: Some links on our site are affiliate links, which means we may earn a commission if you use them, at no extra cost to you. That never changes our editorial conclusions — and this page is built to be useful even if you never click a provider link.

Sources we checked

Educational content only. Not medical advice. Consult your clinician before starting, stopping, or changing hormone therapy.

Last updated: June 5, 2026 · Last verified: June 5, 2026